SCHEMBL537812

SCHEMBL537812

O=C(NCc1ccccc1)C1CN(Cc2ccccc2)c2nc(NCCc3c[nH]c4ccccc34)nc3[nH]nc1c23

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.49
BCHE P06276 4/20 0.46
ACHE P22303 4/20 0.46
GPR18 Q14330 2/20 0.43
HTR1A P08908 4/20 0.41
DRD2 P14416 3/20 0.41
HTR2A P28223 3/20 0.41
HTR7 P34969 3/20 0.41
HTR6 P50406 3/20 0.41
KMT2A Q03164 3/20 0.40
POLB P06746 1/20 0.40
SLC2A1 P11166 1/20 0.40
RAD52 P43351 1/20 0.40
MTNR1A P48039 2/20 0.40
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2815942 0.85 MC4R (0.43) MC4RPOLB
SCHEMBL2811925 0.83 CACNA1G (0.42)
SCHEMBL2812129 0.82 P2RX7 (0.44) KMT2APOLB
SCHEMBL538580 0.81 CACNA1G (0.41) KMT2AMEN1
SCHEMBL538002 0.81 KDM1A (0.41)
SCHEMBL2808450 0.81 MMP13 (0.41) KMT2APOLBMEN1PKM
SCHEMBL2812033 0.81 P2RX7 (0.42) KMT2AMEN1
SCHEMBL2814282 0.80 KMT2A (0.42) KMT2AMEN1
SCHEMBL2812141 0.80 ALDH1A1 (0.43) KMT2APOLBMEN1
SCHEMBL13131765 0.80 KMT2A (0.40) MC4RKMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP claimed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO claimed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 MC4R 3042/4885BCHE 4134/4885ACHE 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.